Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 675-679

  Menczer, Joseph ^a   Schreiber, Letizia ^a   Berger, Esther ^a   Golan, Abraham ^a   Levy, Tally ^a  

^a WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Gestational trophoblastic neoplasia; Her 2 neu; Hydatidiform mole

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOTROPHOBLAST; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FISHER EXACT TEST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; MEDICAL ASSESSMENT; MEDICAL RECORD; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TISSUE SECTION; TROPHOBLASTIC TUMOR;

ADOLESCENT; ADULT; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREGNANCY; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 33846944333     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.10.012     Document Type: Article

References (36)

1. Bagshawe K.D., Lawler S.D., Paradinas F.J., Dent J., Brown P., and Boxer G.M. Gestational trophoblastic tumors following initial diagnosis of partial hydatidiform mole. Lancet 335 (1990) 1074-1076
2. Berkowitz R.S., and Goldstein D.P. Chorionic tumors. N. Engl. J. Med. 335 (1996) 1740-1748
3. Soper J.T. Gestational trophoblastic disease [Clinical Expert Series]. Obstet. Gynecol. 108 (2006) 176-187
4. Lurain J.R., and Elfstrand E.P. Single-agent methotrexate chemotherapy for treatment of nonmetastatic gestational trophoblastic tumors. Am. J. Obstet. Gynecol. 172 (1995) 574-579
5. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001) 783-792
6. Feltmate C.M., Batorfi J., Fulop V., Goldstein D.P., Doszpod J., and Berkowitz R.S. Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation. Obstet. Gynecol. 101 (2003) 732-736
7. Wolfberg A.J., Feltmate C., Goldstein D.P., Berkowitz R.S., and Lieberman E. Low risk of relapse after achieving undetectable hCG levels in women with complete molar pregnancy. Obstet. Gynecol. 104 (2004) 551-554
8. Batorfi J., Vegh G., Szepesi J., Szigetvari I., Doszpod J., and Fulop V. How long should patients be followed after molar pregnancy? Analysis of serum hCG follow-up data. Eur. J. Obstet. Gynecol. Reprod. Biol. 112 (2004) 95-97
9. Curry S.L., Hammond C.B., Tyrey L., Creasman W.T., and Parker R.T. Hydatidiform mole: diagnosis, management, and long-term follow-up of 347 patients. Obstet. Gynecol. 45 (1975) 1-8
10. Parazzini F., Mangili G., Belloni C., La Vecchia C., Liati P., and Marabini R. The problem of identification of prognostic factors for persistent trophoblastic disease. Gynecol. Oncol. 30 (1988) 57-62
11. Genest D.R., Laborde O., Berkowitz R.S., Goldstein D.P., Bernstein M.R., and Lage J. A clinicopathologic study of 153 cases of complete hydatidiform mole (1980-1990): histologic grade lacks prognostic significance. Obstet. Gynecol. 78 (1991) 402-409
12. Ayhan A., Tuncer Z.S., Halilzade H., and Kucukali T. Predictors of persistent disease in women with complete hydatidiform mole. J. Reprod. Med. 41 (1996) 591-594
13. Khazaeli M.B., Hedayat M.M., Hatch K.D., To A.C., Soong S.J., Shingleton H.M., et al. Radioimmunoassay of free beta-subunit of human chorionic gonadotropin as a prognostic test for persistent trophoblastic disease in molar pregnancy. Am. J. Obstet. Gynecol. 155 (1986) 320-324
14. Berkowitz R., Ozturk M., Goldstein D.P., Bernstein M., Hill L., and Wands J.R. Human chorionic gonadotropin and free subunits' serum levels in patients with partial and complete hydatidiform moles. Obstet. Gynecol. 74 (1989) 212-215
15. Mungan T., Kuscu E., Ugur M., Dabakoglu T., Senses E., and Cobanoglu O. Screening of persistent trophoblastic disease with various serum markers. Eur. J. Gynecol. Oncol. 19 (1998) 495-497
16. Shigematsu T., Kamura T., Saito T., Kaku T., Nakano H., and Kinugawa N. Identification of persistent trophoblastic diseases based on a human chorionic gonadotropin regression curve by means of a stepwise piecewise linear regression analysis after the evacuation of uneventful moles. Gynecol. Oncol. 71 (1998) 376-380
17. Wolfberg A.J., Berkowitz R.S., Goldstein D.P., Feltmate C., and Lieberman E. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy. Obstet. Gynecol. 106 (2005) 548-552
18. Jeffers M.D., Richmond J.A., and Smith R. Trophoblast proliferation rate does not predict progression to persistent gestational trophoblastic disease in complete hydatidiform mole. Int. J. Gynecol. Pathol. 15 (1996) 34-38
19. Okamoto T., Matsuo K., Niu R., Osawa M., and Suzuki H. Human chorionic gonadotropin (hCG) beta-core fragment is produced by degradation of hCG or free hCG beta in gestational trophoblastic tumors: a possible marker for early detection of persistent postmolar gestational trophoblastic disease. J. Endocrinol. 171 (2001) 435-443
20. Koonings P.P., and Schalerth J.B. CA-125: a marker for persistent gestational trophoblastic disease?. Gynecol. Oncol. 49 (1993) 240-242
21. Mungan T., Kuscu E., Ugur M., Dabakoglu T., Senses E., and Cobanoglu O. Screening of persistent trophoblastic disease with various serum markers. Eur. J. Gynaecol. Oncol. 19 (1998) 495-497
22. Kohorn E.I. Measurement of CA-125 in trophoblastic disease. Gynecol. Oncol. 78 (2000) 39-42
23. Gurian K.V., Podratz K.C., Elg S.A., Twiggs L.B., Lurain J.R., Wagner J.M., et al. Major basic protein as a marker of malignant potential in trophoblastic neoplasia. Am. J. Obstet. Gynecol. 175 (1996) 632-637
24. Petignat P., Boulvain M., and Vassilakos P. Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation. (Letter). Obstet. Gynecol. 102 (2003) 642-643
25. Bae S.N., and Kim S.J. Telomerase activity in complete hydatidiform mole. Am. J. Obstet. Gynecol. 180 (1999) 328-333
26. Kohorn E.I., Kacinski B.M., and Stanley E.R. Serum levels of macrophage colony stimulating factor in trophoblastic disease. Gynecol. Oncol. 80 (2001) 383-386
27. Duc H.N., van Trommel N.E., Sweep F.C., Massuger L.F., and Thomas C.M. Clinical utility of hyperglycosylated hCG in serum taken before hydatidiform mole evacuation to predict persistent trophoblastic disease. Int. J. Biol. Markers 21 (2006) 45-49
28. Cole L.A., Butler S.A., Khanlian S.A., Giddings A., Muller C.Y., Seckl M.J., et al. Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia. Gynecol. Oncol. 102 (2006) 151-159
29. Fulop V., Vegh G., and Doszpod J. The c-erbB-related oncoproteins in normal placenta and in gestational trophoblastic diseases (in vitro study). Orv. Hetil. 142 (2001) 1147-1154 [Article in Hungarian]
30. Makovitzky J., Vogel M., Miessner R., Mylonas I., Vogt-Weber B., and Richter D.U. Diagnostic aspects of hydatidiform mole with persistence of polymorphic trophoblastic hyperplasia. Anticancer Res. 23 (2003) 1069-1073
31. Matalon M., Paz B., Modan M., and Modan B. Malignant trophoblastic disorders. Epidemiologic aspects and relationship to hydatidiform mole. Am. J. Obstet. Gynecol. 112 (1972) 101-106
32. Menczer J., Modan M., and Serr D.M. Prospective follow-up of patients with hydatidiform mole. Obstet. Gynecol. 55 (1980) 346-349
33. Czernobilsky B., Barash A., and Lancet M. Partial moles: a clinicopathologic study of 25 cases. Obstet. Gynecol. 59 (1982) 75-77
34. Zalel Y., and Dgani R. Gestational trophoblastic disease following the evacuation of partial hydatidiform mole: a review of 66 cases. Eur. J. Obstet. Gynecol. Reprod. Biol. 71 (1997) 67-71
35. Menczer J., Girtler O., Zajdel L., and Glezerman M. Metastatic trophoblastic disease following partial hydatidiform mole: case report and literature review. Gynecol. Oncol. 74 (1999) 304-307
36. Cole L.A., Khanlian S.A., Giddings A., Butler S.A., Muller C.Y., Hammond C., and Kohorn E. Gestational trophoblastic diseases: 4. Presentation with persistent low positive human chorionic gonadotropin test results. Gynecol. Oncol. 102 (2006) 165-172